In conclusion, we confirmed that Cilostazol protects against DCM injury by reducing inflammation and pyroptosis in a TXNIP-depenent manner via downregulating the TXNIP-NLRP3 pathway. Here, NLRP3 is linked to familial dilated cardiomyopathy.